Document:

EX-10.57

 Exhibit 10.57 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF
ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE
SECURITIES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND APPLICABLE STATE SECURITIES LAWS. 

FIRST PHYSICIAN’S CAPITAL GROUP, INC. 

PROMISSORY NOTE 
  

			
	$                            	  	November 20, 2013

 FIRST PHYSICIAN’S CAPITAL GROUP, INC., a Delaware corporation (“Company”), for
value received, promises to pay             , a             , or its assigns (“Holder”) the principal sum
of             , plus simple interest thereon from the date in which funds are actually advanced under this Promissory Note (this “Note”) until paid at the
rate of ten percent (10%) per annum until the Maturity Date (as defined below), cumulative, but not compounded. The Company hereby acknowledges and agrees that principal amount hereof is to be advanced
in             installments as follows:             . 

This Note is issued in connection with the sale and issuance of up to Six Hundred Fifty Thousand Dollars ($650,000) in principal amount of
senior promissory notes (the “Notes”). Each Note shall rank on a pari passu basis in all respects with all other Notes issued in such financing (the “Bridge Financing”) and all such Notes shall
be repaid by the Company on a pari passu, pro rata basis. 
 This Note will automatically mature and the entire outstanding principal
amount, together with accrued interest, shall become due and payable in one lump sum upon date that is the earlier of: (i) June 30, 2014; (ii) the consummation of a Change of Control (as defined below), or (iii) an Event of
Default (as defined below) that is followed by written notice by a Required Majority (as defined below) pursuant to Section 2 hereof (such first date to occur being the “Maturity Date”). For purposes of this Note, a
“Change of Control” shall mean: (i) any sale of all or substantially all of the Company’s assets, other than in the ordinary course of the conduct of the Company’s business, (ii) a merger or acquisition in
which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the State of the Company’s incorporation or formation, as the case may be, (iii) any reverse merger in which the Company is
the surviving entity but in which the then existing shareholders or members of the Company transfer fifty percent (50%) or more of the outstanding shares or equity interests of the Company, as the case may be, of such then existing shareholders
to holders different from those who held such shares immediately prior to such merger; and/or (iv) any sale or transfer by the then existing shareholders or members of the Company of fifty percent (50%) or more of the outstanding shares or
interests of the Company of such then existing shareholders or members to any person or persons other than the then existing shareholders or members of the Company. 

Payments of both principal and interest are to be made at the address of Holder or at such other place in the United States as Holder shall
designate to the Company in writing, in lawful money of the United States of America. Interest on this Note shall be computed on the basis of a 365-day year and actual days elapsed. 

 The following is a statement of the rights of Holder and the conditions to which this Note is
subject, and to which Holder, by the acceptance of this Note, agrees: 
 1. Prepayment. All unpaid principal and unpaid accrued
interest of this Note may be prepaid without penalty, in whole or in part. Any prepayment of this Note will be credited first against accrued interest, then principal. Upon payment in full of the amount of all principal and interest payable
hereunder, this Note shall be surrendered to the Company for cancellation. 
 2. Charges, Taxes and Expenses. Issuance of this Note
shall be made without charge to Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Note, all of which taxes and expenses shall be paid by the Company, and such Note(s) shall be issued in the name of
Holder. 
 3. Default. Each of the following events shall be an “Event of Default” hereunder: 

(a) The Company fails to pay timely any of the principal amount, accrued interest or other amounts due under this Note on the date any of the
same becomes due and payable if such payment default is not cured within thirty (30) business days after receipt of notice of such default from Holder; 

(b) The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for
the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any limited liability action in furtherance of any of the foregoing; 

(c) An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within thirty (30) days) under
any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company; or 

(d) The Company shall fail to observe or perform any other material obligation to be observed or performed by it under this Note, within thirty
(30) days after written notice from the Holder to perform or observe the obligation. 
 Upon the occurrence of an Event of Default
hereunder, all unpaid principal, accrued and unpaid interest and other amounts owing hereunder shall, at the option of, and upon written notice provided to the Company by Holder, be immediately due, payable and collectible by Holder, pursuant to
applicable law without presentment, demand, protest, notice of any kind or notice of dishonor, all of which are hereby expressly waived; provided, however, that upon the occurrence of any of the events specified in subparagraphs (b) or
(c) above, all unpaid principal, accrued and unpaid interest and other amounts owing hereunder, shall be immediately due and payable without any notice whatsoever and without presentment, demand for payment, protest, notice of any kind or
notice of dishonor, all of which are hereby expressly waived by the Company. If an Event of Default occurs and is continuing, the Holder may pursue any available remedy by proceeding at law or in equity to collect the payment of amounts due under
the Notes or to enforce the performance of any provision of the Note. A delay or omission by the Holder in exercising any right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or
acquiescence in the Event of Default. A waiver on any one occasion shall not be construed as a bar to or waiver of any such right or remedy on any future occasion. No remedy is exclusive of any other remedy. All available remedies are cumulative to
the extent permitted by law. 

  
 2 

 4. Subordination by Prior Bridge Lenders. The Company has previously consummated a bridge
financing transaction with in 2009 purchasers (the “2009 Lenders”) pursuant to the terms of and as evidenced by bridge notes (the “2009 Bridge Notes”). As a material inducement for Holder to enter into this Bridge
Financing, concurrently herewith the 2009 Lenders will enter into a subordination agreement to subordinate all rights of the 2009 Lenders under the 2009 Bridge Notes to rights of Holders of the Notes issued in this Bridge Financing. 

5. Usury Exemption. As applicable, this Note shall be issued in reliance on an exemption from applicable state usury laws found in
Section 25118 of the California Corporations Code. Notwithstanding any provision of this Note, the Company shall not and will not be required to pay interest at a rate or any fee or charge in an amount prohibited by applicable law. If interest
or any fee or charge payable on any date would be prohibited, then such interest, fee or charge will be automatically reduced to the maximum amount that is not prohibited. In the event that Holder receives payment of any interest, fee, or charge
that would cause the amount so received to exceed the maximum amount permitted under applicable law, then, to the extent that the amount so received exceeds the maximum amount permitted under applicable law: (a) in the first instance, the
amount received shall be applied to principal; and (b) in the second instance, in the event that the principal amount of this Note has been paid in full, the remaining amount so received shall be deemed to be a loan from Company to the Holder,
repayable upon the demand of the Company with interest at the legal rate from the date of the Holder’s receipt of each payment in excess interest, fees, or charges. 

6. Loss, Theft or Destruction of Note. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft or
destruction of this Note and of indemnity or security reasonably satisfactory to it, the Company will make and deliver a new Note which shall carry the same rights to interest (unpaid and to accrue) carried by this Note, stating that such Note is
issued in replacement of this Note, making reference to the original date of issuance of this Note (and any successors hereto) and dated as of such cancellation of this Note. 

7. Miscellaneous. 
 (a)
Governing Law; Arbitration. This Note shall constitute a contract under the laws of the State of Delaware and for all purposes shall be construed in accordance with and governed by the laws of said state, excluding its conflicts of law
principles. The parties to this Note agree that any and all disputes, claims or controversies arising out of or relating to this Note that are not resolved by their mutual agreement shall be submitted to final and binding arbitration in Los Angeles
County, California before JAMS, or its successor, pursuant to the United States Arbitration Act, 9 U.S.C. Sec. 1 et seq. Either party may commence the arbitration process called for in this Note by filing a written demand for arbitration with JAMS,
with a copy to the other party. The arbitration will be conducted in accordance with the provisions of JAMS’ Streamlined Arbitration Rules and Procedures in effect at the time of filing of the demand for arbitration. The parties will cooperate
with JAMS and with one another in selecting an arbitrator from JAMS’ panel of neutrals, and in scheduling the arbitration proceedings. The parties covenant that they will participate in the arbitration in good faith, and that they will share
equally in its costs. The provisions of this Section may be enforced by any court of competent jurisdiction, and the party seeking enforcement shall be entitled to an award of all costs, fees and expenses, including reasonable attorneys’ fees,
to be paid by the party against whom enforcement is ordered. 
 (b) Assignment. Neither this Note nor any of the rights, interests or
obligations hereunder may be assigned, by operation of law or otherwise, in whole or in part by the Holder to any person or entity without the prior written consent of the Company, in its sole and absolute discretion; provided, however, that this
Note may be assigned or transferred, in whole or in part, without the prior written consent of the Company for bona fide estate planning purposes or to an affiliate, subsidiary, partner (limited or otherwise) and/or member of the Holder. Upon any
transfer of this Note, the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax 

  
 3 

 
incidental thereto. Any transfer shall be subject to (i) the transferee’s agreement in writing to be subject to the applicable terms of this Note; (ii) compliance with all
applicable state and federal securities laws (including the delivery of legal opinions reasonably satisfactory to the Company, if such are reasonably requested by the Company); and (iii) the execution and delivery to the Company of an
Assignment Form in substantially the form attached hereto as Attachment A. This Note shall be binding upon any successors or assigns of the Company. 

(c) Notices. All notices, requests, demands and other communications hereunder (shall be in writing to the parties at the addresses set
forth below the recipients’ signature to this Note, or at such other address as shall be given in writing by a party to the other parties, and shall be deemed to have been duly given at the earlier of (i) the time of actual delivery,
(ii) the next business day after deposit with a nationally recognized overnight courier specifying next day delivery, with written verification of receipt, (iii) when sent by facsimile or electronic mail communication if receipt is
confirmed, or (iv) on the fifth (5th) business day following the date deposited with the United States Postal Service, postage prepaid, certified with return receipt requested. 

(d) Cross Default. An Event of Default under this Note shall be an event of default under all other Notes issued in connection with the
Bridge Financing. In such event, the Holder shall be entitled to exercise any remedies available to it pursuant hereto or at law, including, without limitation, accelerate and declare all of the obligations hereunder to be immediately due and
payable. 
 (e) Amendment or Waiver. Both this Note and the terms and conditions of the Bridge Financing, including, without
limitation, the aggregate value of the Notes issued thereunder, may be amended or a provision hereof waived only in a writing signed by the Company and a Required Majority (as defined below); provided, however, that any such amendment
or waiver shall apply to all Notes issued in the Bridge Financing. For purposes of this Note, a “Required Majority” shall mean holders holding, at the time of any determination, a majority-in-interest of the then-outstanding
principal amount of all Notes subscribed for pursuant to the Bridge Financing. The Holder acknowledges that a Required Majority will have the right and power to diminish or eliminate all rights of the Holder hereunder. 

(f) Survival. The provisions which, by their nature, would survive any expiration, termination and/or cancellation of this Agreement
shall survive any such termination, expiration and/or cancellation of the business relationship among the parties, this Agreement and/or the dissolution, termination and winding up of the Company 

(g) Accredited Investor. The Holder hereby represents that it is an “accredited investor” within the meaning of Regulation D,
Rule 501(a), promulgated by the Securities and Exchange Commission under the 1933 Act and shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. If Holder has previously made an investment
with the Company under the same investor name and, in connection with such investment, the Holder provided the Company with representations and warranties confirming, among other things, its status as an accredited investor and/or a signed Investor
Questionnaire (the “Prior Investor Representations”), Investor hereby represents and warrants that all such information set forth in the Prior Investor Representations is complete, true, correct
and accurate as of the date hereof. In such case, holder shall not be required to complete and execute an additional investor questionnaire in connection with the purchase of this Note. If Holder has not previously made an investment in the Company,
Holder shall execute and deliver to the Company its standard investor questionnaire together with the purchase price for this Note certifying that Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D
promulgated under Section 4(2) of the Securities Act of 1933. 
 (h) Acknowledgments. The Holder hereby acknowledges and
understands that: 

  
 4 

 (i) There are substantial restrictions on the transferability of the Notes, including, but not
limited to, those imposed by federal and/or state securities laws. 
 (ii) At no time has any of the following ever been represented,
guaranteed or warranted to the Holder by the Company, nor any of its agents or employees or any other person, expressly or by implication: 

(1) The percentage or profit and/or the amount of or type of consideration, profit or loss to be realized if any, as a result
of Holder’s investment; 
 (2) That the past performance or experience on the part of the Company, or any affiliate
thereof, will in any way indicate the predictable results of the ownership of the Notes; or 
 (3) That an investment in the
Company will yield the percentage of profit and/or amount of or type of consideration, profit or loss similar to that yielded by other projects managed by the Company or its affiliates. 

(iii) Holder has adequate net worth and means of providing for his, her or its current needs and possible personal contingencies to sustain a
complete loss of this investment and has no need for liquidity of this investment. Holder’s total commitment to investments which are not readily marketable is not disproportionate to the Investor’s net worth and will not become
disproportionate as a result of the Investor’s investment in the Notes. Holder has such knowledge and experience in financial and business matters that Holder is capable of evaluating the merits and risks of investment in the Company, and
Holder is able to bear the economic risk of Holder’s investment in the Company and at the present time Holder could afford a complete loss of Holder’s investment. 

(iv) Holder recognizes that investment in the Company involves substantial risks, including a risk of total loss of Holder’s investment,
and Holder is aware of and understands all of the risk factors related to Holder’s purchase of Notes. Holder is either a director or officer of the Company and is intimately familiar with the Company’s operations (including the risks
associated therewith), or has had an opportunity to fully discuss such Holder’s investment with the Company’s officers, directors or management and has received all information which Holder considers necessary or appropriate for deciding
whether to acquire the Note. 
 (v) Holder represents that it is acquiring this Note solely for investment for such Holder’s own
account not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 5 

 IN WITNESS WHEREOF, the Company has caused this Promissory Note to be executed by its officer
thereunto duly authorized. 
  

			
	COMPANY:
	
	 FIRST PHYSICIAN’S CAPITAL GROUP, INC.,

a Delaware corporation

		
	By:	 	  

	Sean Kirrane, Chief Executive Officer

 ACKNOWLEDGED AND AGREED TO: 
  

 

			
	HOLDER:
		
	By:	 	  

		 	Name, Title

 [SIGNATURE PAGE TO PROMISSORY
NOTE] 

 ATTACHMENT A TO SENIOR PROMISSORY NOTE 

ASSIGNMENT FORM 
 (To assign the
foregoing Note, execute 
 this form and supply required information.) 

FOR VALUE RECEIVED, and subject to compliance with applicable federal and state securities laws (including the delivery of legal opinions
satisfactory to the Company, if such are requested by the Company), an interest corresponding to the unpaid principal amount of the foregoing Note and all rights evidenced thereby are hereby assigned to 

 
  

(Please Print) 
  

							
	
	 whose address
is                                        
                                         
                                         
                                         
                         

	
	
Dated:                        
                                         
                                         
                          

	
	 Holder’s
Signature:                                       
                                         
                                

		
	 Holder’s
Address:                                       
                                         
                                    
	  	
		
	
                         
   __________________________________________________________
	  	
	
	 Signature
Guaranteed:                                       
                                         
                    

  

							
	NOTE:	 	The signature to this Assignment Form must correspond with the name as it appears on the face of the Note, without alteration or enlargement or any change whatever, and must be guaranteed by a bank or trust company.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Note.
		
		 	The assignee of the Note, in connection with the execution of this Assignment Form, must execute and deliver an acknowledgment of, and agreement to be bound by, the terms of the Note and all other writings related
thereto.

 ATTACHMENT A TO NOTEEX-10.58

 Exhibit 10.58 

FIRST PHYSICIANS CAPITAL GROUP, INC. 

(A Delaware Corporation) 
  

 
 WARRANT TO
PURCHASE 
 SHARES OF COMMON STOCK 
  

 
 Effective:
January 1, 2014 
 THE OFFER AND SALE OF THIS WARRANT (THIS “WARRANT”) AND THE SECURITIES ISSUABLE UPON THE
EXERCISE THEREOF (THE “UNDERLYING SECURITIES”) HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE LAWS OF ANY STATE. THIS WARRANT AND THE UNDERLYING
SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED, MORTGAGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT WITH RESPECT TO SUCH TRANSFER OR AN OPINION OF
ISSUER’S LEGAL COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH REGISTRATION UNDER THE SECURITIES ACT IS NOT REQUIRED BY VIRTUE OF AN AVAILABLE EXEMPTION THEREFROM. 

THIS CERTIFIES THAT, for value received,             ,
a             , or its registered assigns (“Holder”), is entitled to purchase, subject to the conditions set forth below, at any time or from time to time during the
Exercise Period (as defined in Section 1.2 below),             shares (“Shares”) of fully paid and non-assessable
common stock, par value $0.01 per share (the “Common Stock”), of First Physicians Capital Group, Inc., a Delaware corporation (the “Company”), at the per share purchase price set forth in Section 1.1
below (the “Warrant Price”), subject to the further provisions of this Warrant. 
 1. EXERCISE OF WARRANT 

The terms and conditions upon which this Warrant may be exercised, and the Shares subject hereto may be purchased, are as follows: 

1.1 Warrant Price. The Warrant Price shall be $0.3125 per Share, subject to adjustment as provided in Section 4 below. 

1.2 Method of Exercise. Holder may at any time beginning on the effective date of this Warrant and until January 1, 2019, or such
later date as the Company may in its sole discretion determine (the “Exercise Period”), exercise in whole or in part the purchase rights evidenced by this Warrant. Such exercise shall be effected by: 

 (a) the surrender of this Warrant, together with a duly executed copy of the form
of notice of exercise (the “Exercise Notice”) attached hereto as Exhibit A, to the Secretary of the Company at its principal office; 

(b) the payment to the Company, by cash or wire transfer to the Company’s account, of an amount equal to the aggregate
Warrant Price for the number of Shares for which the purchase rights hereunder are being exercised. Alternatively if then permitted under applicable securities laws, Holder may exercise this Warrant by delivering to the Company: (i) a properly
executed notice of exercise together with a copy of irrevocable instructions (“Broker Instructions”) to a FINRA-member securities broker to promptly deliver to the Company cash or a check payable to the Company in the full amount of
the Warrant Price for the total number of Shares being purchased against the Company’s delivery of the Shares for which this Warrant is exercised (if the Holder and the securities broker comply with such procedures and enter into such
agreements of indemnity and other agreements as the Company may reasonably prescribe as a condition of that payment procedure) or (ii) shares of Common Stock beneficially owned by Holder, which shall be free and clear of any and all liens,
claims and encumbrances, having an aggregate Fair Market Value (as defined herein below) equal to the full amount of the Warrant Price for the total number of Shares being purchased. The Holder may also make payment in any combination of the
permissible forms of payment described in the preceding sentence. Additionally, if then permitted under applicable securities laws, if the Fair Market Value of the Shares at time of exercise is greater than the Warrant Price, the Holder may exercise
this Warrant or any portion hereof by indicating on the notice of exercise that the Holder elects to exercise this Warrant on a net exercise basis (“Net Exercise Basis”). The Company shall then issue to the Holder a number of Shares
determined using the following formula: 
  
 

 
 where 
  

							
				
		 		 	X =	  	the number of Shares to be issued to the Holder.
				
		 		 	Y =	  	the number of Shares covered by this Warrant in respect of which the net exercise election is made pursuant to this Section.
				
		 		 	A =	  	the Fair Market Value of one Share, as determined in accordance with the provisions hereof, as of the date this Warrant is exercised.
				
		 		 	B =	  	the Warrant Price in effect as of the date this Warrant is exercised.

 Fair Market Value of a share of Common Stock (for purposes of this section) means (a) if
the Shares are traded on a national securities exchange, the average of the closing prices for the twenty (20) trading days prior to the date this Warrant is exercised; (b) if the Shares are traded on the OTC Bulletin Board or another
market or quotation system, or the prices for the shares are published on the “Pink Sheets” operated by the Pink Sheets LLC, the average of the closing bid and ask prices posted for the Shares during the twenty (20) trading days prior
to the date this Warrant is exercised; or (c) if the primary market for such Shares is not an exchange or quotation system, the fair market value thereof as shall be determined in good faith using appropriate valuation methods by the Board of
Directors of the Company as of the date this Warrant is exercised; and 

  
 2 

 (c) the delivery to the Company, if necessary in the discretion of counsel for
the Company, to assure compliance with the Securities Act of 1933, as amended (the “Securities Act”), and applicable state securities laws, of an instrument executed by holder certifying that the Shares are being purchased solely
for the account of Holder and not with a view to any resale or distribution in violation of the Securities Act or applicable state securities laws. 

1.3 Issuance of Shares and New Warrant. If the purchase rights evidenced by this Warrant are exercised in whole or in part, one or more
certificates for the purchased Shares shall be issued as soon as practicable thereafter to Holder. If the purchase rights evidenced by this Warrant are exercised only in part, the Company shall also deliver to Holder at such time a new warrant
evidencing the purchase rights regarding the number of Shares (if any) for which the purchase rights under this Warrant remain unexercised and continue in force and effect. All new warrants issued in connection with the provisions of this
Section 1.3 shall bear the same date as this Warrant and shall be substantially identical in form and provisions to this Warrant except for the number of Shares purchasable thereunder. Each person in whose name any certificate for Shares
is to be issued shall for all purposes be deemed to have become the holder of record of such Shares on the date on which this Warrant was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such stock
certificate, except that if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such Shares at the close of business on the next
succeeding date on which the stock transfer books are open. 
 2. TRANSFERS 

2.1 Transfers. This Warrant and all rights hereunder are transferable in whole or in part by the Holder subject to the provisions of
Section 7 below. The transfer shall be recorded on the books of the Company upon (i) the surrender of this Warrant (together with a duly executed and endorsed copy of the form of transfer certificate attached hereto as Exhibit
B) to the Secretary of the Company at its principal offices, and (ii) the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. In the event of a partial transfer, the Company shall issue to
the several holders one or more appropriate new warrants. 
 2.2 Registered Holder. Each holder of this Warrant agrees that until such
time as any transfer pursuant to Section 2.1 above is recorded on the books of the Company, the Company may treat the registered Holder of this Warrant as the absolute owner. 

2.3 Form of New Warrants. All new warrants issued in connection with transfers of this Warrant shall bear the same date as this Warrant
and shall be substantially identical in form and provisions to this Warrant except for the number of Shares purchasable thereunder. 
 3. NO
FRACTIONAL SHARES 
 Notwithstanding any adjustment (as required hereby) to the number of Shares purchasable upon the exercise of this
Warrant, the Company shall not be required to issue any fraction of a Share upon exercise of this Warrant. If, by reason of any change made pursuant to Section 4 below, the Holder would be entitled, upon the exercise of any rights evidenced
hereby, to receive a fractional interest in a Share, the Company shall, upon such proper exercise of this Warrant, purchase such fractional interest for an amount in cash equal to the Fair Market Value of such fractional interest, determined as of
the date of such exercise of this Warrant. 

  
 3 

 4. ANTIDILUTION PROVISIONS 

4.1 Stock Splits and Combinations. If the Common Stock shall at any time be subdivided into a greater number of shares, then the number
of Shares purchasable upon exercise of this Warrant shall be proportionately increased and the Warrant Price shall be proportionately decreased; and, conversely, if the Common Stock shall at any time be combined into a smaller number of shares, then
the number of Shares purchasable upon exercise of this Warrant shall be proportionately reduced and the Warrant Price shall be proportionately increased. Any adjustments under this Section 4.1 shall become effective at the close of
business on the date the subdivision or combination becomes effective. 
 4.2 Reclassification, Exchange and Substitution. If the
Common Stock shall be changed into shares of any other class or classes of stock or other securities of the Company, whether by capital reorganization, reclassification, or otherwise, Holder shall, upon exercise of this Warrant, be entitled to
purchase for the same aggregate consideration, in lieu of the Shares that Holder would have become entitled to purchase but for such change, such number, class and series of securities of the Company as would have been issuable in connection with
such event to a holder of that number of shares of Common Stock purchasable upon exercise of this Warrant immediately prior to such reorganization, reclassification or other change. The Warrant Price shall be appropriately adjusted to reflect that
reorganization, reclassification or other change. Any adjustments under this Section 4.2 shall become effective at the close of business on the date such change of the Common Stock into shares of any other class or classes of stock or
other securities of the Company becomes effective. 
 4.3 Reorganizations, Mergers, Consolidations or Sale of Assets. If at any time
there shall be a reorganization involving the Common Stock (other than a stock split, combination, reclassification, exchange, or subdivision of shares provided for in Sections 4.1 and 4.2 above) or a merger or consolidation of the
Company with or into another corporation, or the sale of all or substantially all of the Company’s assets to any other person, then, as a part of such reorganization, merger, consolidation or sale, lawful provision shall be made so that Holder
shall thereafter be entitled to receive upon exercise of this Warrant, in accordance with the terms hereof, in lieu of the Shares that Holder would have become entitled to purchase but for such event, such other securities or property of the
Company, or of the successor corporation resulting from such event, to which Holder would have been entitled in such reorganization, merger, consolidation or sale if this Warrant had been exercised immediately before that reorganization, merger,
consolidation or sale. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of
Holder after the reorganization, merger, consolidation, or sale to the end that the provisions of this Warrant (including adjustment of the Warrant Price then in effect and number of Shares purchasable upon exercise of this Warrant) shall be
applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant. The Company shall provide Holder with at least twenty (20) days’ prior
written notice of any of the events described in the first sentence of this Section 4.3. 
 4.4 Adjustments of Other
Distributions. If the Company shall at any time declare and pay or deliver to the holders of Common Stock a distribution payable in securities of other persons, evidences of indebtedness issued by the Company or other persons, assets (excluding
cash dividends) or options or rights, in any case of a kind not referred to above, then, upon exercise of this Warrant, Holder shall be entitled to receive a proportionate share of any such distribution as though Holder was the holder of the number
of shares of Common Stock into which this Warrant may be exercised as of the record date fixed for the determination of the holders of Common Stock entitled to receive such distribution. 

4.5 Certificate as to Adjustments. In the case of an event requiring adjustment under this Section 4, the Company will, as
soon as reasonably practicable following such event requiring the adjustment, compute such adjustment in accordance with the terms hereof and notify Holder of the event requiring adjustment and the calculations and results of such adjustment. 

  
 4 

 4.6 Reservation of Stock Issuable Upon Exercise. The Company shall at all times reserve
and keep available out of its authorized but unissued shares of Common Stock such number of shares of Common Stock as shall from time to time be sufficient to effect the exercise of this Warrant. If at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to
such number of shares as shall be sufficient for such purpose. 
 4.7 Method of Calculation. All calculations under this
Section 4 shall be made to the nearest one hundredth of a share. 
 5. RIGHTS PRIOR TO EXERCISE OF WARRANT 

This Warrant does not entitle Holder to any of the rights of a stockholder of the Company, including (without limitation) the right to receive
dividends or other distributions, to vote or consent, or to receive notice as a stockholder of the Company. If, however, at any time prior to the expiration of this Warrant and prior to its exercise, 

(a) the Company shall declare any dividend payable in any securities upon outstanding shares of Common Stock or make any other
distribution (other than a regular cash dividend) to the holders of shares of Common Stock; 
 (b) the Company shall offer to
the holders of shares of Common Stock any additional shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock or any right to subscribe for or purchase any thereof; or 

(c) a dissolution, liquidation or winding-up of the Company (other than in connection with a reorganization, consolidation,
merger, or sale of all or substantially all of its assets as an entirety) shall be approved by the Company’s Board of Directors, 
 then, in any one or
more of such events the Company shall give notice in writing of such event to Holder, at its address as it shall then appear on the Company’s records, at least twenty (20) days prior to the date fixed as a record date or the date of
closing the transfer books for the determination of the stockholders entitled to such dividends, distribution, or subscription rights, or for the determination of stockholders entitled to vote on such proposed dissolution, liquidation or winding-up.
Such notice shall specify such record date or the date of closing the transfer books, as the case may be. 
 Any failure to give such notice
or any defect therein, however, shall not affect the validity of any action taken in connection with such dividend, distribution or subscription rights, or such proposed dissolution, liquidation or winding-up. 

6. SUCCESSORS AND ASSIGNS 
 The
terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Holder and its successors and permitted assigns. 

7. RESTRICTED SECURITIES 
 To
enable the Company to comply with the Securities Act and applicable state securities laws, the Company may require Holder, as a condition of the transfer or exercise of this Warrant, to give written assurance satisfactory to the Company that this
Warrant, or in the case of an exercise hereof the Shares, are being acquired for its own account, for investment only, with no view to the distribution of the same in violation of the Securities Act or applicable state securities laws. Any
disposition of all or any portion of this Warrant or the Shares shall not be made unless and until: 

  
 5 

 (a) There is then in effect a registration statement under the Securities Act
covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (b)
Holder has (i) notified the Company of the proposed disposition and furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (ii) furnished the Company with an opinion of counsel,
satisfactory to the Company, that such disposition will not require registration of such securities under the Securities Act and applicable state securities laws. 

Holder acknowledges that this Warrant is, and each of the Shares issuable upon the exercise hereof will be, a restricted security, and that
the certificate or certificates evidencing such Shares will bear a legend substantially similar to the following: 
 “The offer and
sale of the shares represented by this certificate has not been registered under the Securities Act of 1933, as amended, or under the securities laws of any state. They may not be offered, sold, transferred, assigned, pledged, mortgaged,
hypothecated or otherwise disposed of in the absence of an effective registration statement covering these securities under such Act or laws, or an opinion of counsel satisfactory to the Company and its counsel that registration is not required
thereunder.” 
 8. LOSS OR MUTILATION 

Upon receipt by the Company of satisfactory evidence of the ownership of and the loss, theft, destruction, or mutilation of this Warrant, and
(i) in the case of loss, theft, or destruction, upon receipt by the Company of indemnity satisfactory to it, or (ii) in the case of mutilation, upon receipt of this Warrant and upon surrender and cancellation of this Warrant, the Company
shall execute and deliver in lieu thereof a new Warrant representing the right to purchase an equal number of Shares. 
 9. NOTICES 

All notices, requests, demands and other communications under this Warrant shall be in writing and shall be deemed to have been duly given on
the date of receipt (or refusal of receipt) if delivered personally or by courier by the party to whom notice is to be given, or on the earlier of the third business day after the date of mailing or receipt if mailed to the party to whom notice is
to be given by first class mail, registered or certified, postage prepaid, and properly addressed as follows: if to Holder, at its address as shown in the Company’s records; and if to the Company, at its principal office. Either party may
change its address for purposes of this Section 9 by giving the other party written notice of the new address in the manner set forth above. 

10. GOVERNING LAW; JURISDICTION 

This Warrant shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and
performance of this Warrant and all disputes arising hereunder shall be governed by, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware. Any suit, action or proceeding seeking to enforce any provision of, or based on any dispute or matter arising out of or in connection
with, this Warrant must be brought in the state and federal courts located in Los Angeles, County, California. The Company and the Holder each (a) consent to the exclusive jurisdiction of such courts (and of the appropriate appellate courts
therefrom) in any such suit, action or proceeding, (b)

  
 6 

 
irrevocably waive, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or
that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient forum, (c) will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court,
and (d) will not bring any action relating to this Warrant in any other court. 
 [REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed on its behalf by one of
its officers thereunto duly authorized as of January 1, 2014. 
  

			
	FIRST PHYSICIANS CAPITAL GROUP, INC.
		
	By:	 	  

		 	Sean Kirrane
		 	Chief Executive Officer

  
 8 

 EXHIBIT A 

NOTICE OF EXERCISE 
 First Physicians
Capital Group, Inc. 
 9663 Santa Monica Boulevard, Suite 959 

Beverly Hills, CA 90210 
 Gentlemen: 

The undersigned,                 , hereby elects to purchase, pursuant to the
provisions to the foregoing Warrant held by the undersigned,                 shares of the Common Stock, par value $0.01 (the “Common Stock”), of First
Physicians Capital Group, Inc. 
 The undersigned (check one and complete): 

            herewith encloses the Warrant and cash or has made a wire transfer to the
Company’s account in the amount of $            in payment of the Warrant Price. 

            herewith encloses the Warrant and a copy of the applicable Broker Instructions, as
defined in Section 1.2 of the Warrant. 
 The undersigned hereby represents and warrants as follows: 

(a) the undersigned is acquiring such shares of the Common Stock for its own account for investment and not for resale or with a view to
distribution thereof in violation of the Securities Act of 1933, as amended, and the regulations promulgated thereunder (the “Securities Act”); and 

(b) the undersigned is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act and, if
an entity, was not organized for the purpose of acquiring the Warrant or such shares of the Common Stock. The undersigned’s financial condition is such that it is able to bear the risk of holding such securities for an indefinite period of time
and the risk of loss of its entire investment. The undersigned has sufficient knowledge and experience in investing in companies similar to the Company so as to be able to evaluate the risks and merits of its investment in the Company. 

Please issue a certificate or certificates for such shares of the Common Stock in the following name or names and denominations and deliver
such certificate or certificates to the person or persons listed below at their respective address set forth below: 
  

					
		 	  
	  	
			
		 	  
	  	
			
		 	  
	  	
			
		 	  
	  	

 If said number of shares of the Common Stock shall not be all the shares of the Common Stock issuable upon
exercise of the attached Warrant, a new Warrant is to be issued in the name of the undersigned for the remaining balance of such shares of the Common Stock less any fraction of a share of the Common Stock paid in cash pursuant to
Section 3 of the attached Warrant. 
 DATED:            ,
             
  

			
	 Signature:
	 	 
		
	 Address:
	 	 
		 	 

 EXHIBIT B 

ASSIGNMENT FORM 
 FOR
VALUE RECEIVED the undersigned registered owner of this Warrant hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned under this Warrant, with respect to the number of Shares of Common Stock set forth
below: 
  

					
	Name and Address of Assignee	 	 	  	 No. of Shares

Common Stock

	 	 		  	 
	 	 		  	
	 	 		  	

 and does hereby irrevocably constitute and appoint as Attorney
                to register such transfer on the books of                 maintained for
the purpose, with full power of substitution in the premises. 
 Dated:             ,
             
  

			
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

 NOTICE: The signature to this assignment must correspond with the name as written upon the face of the within Warrant in
every particular, without alternation or enlargement or any change whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]